|
|
1 - 1-Introduct-on.pdf
|
PDF
|
354 KB
|
|
|
1 - Introduction.mp4
|
MP4
|
34.8 MB
|
|
|
10 - 3-2-PM.pdf
|
PDF
|
173.5 KB
|
|
|
10 - Priorizitation of Project Pipeline.mp4
|
MP4
|
17.8 MB
|
|
|
11 - 3-3-PM.pdf
|
PDF
|
248.1 KB
|
|
|
11 - Project Phases.mp4
|
MP4
|
36 MB
|
|
|
12 - 3-4-PM.pdf
|
PDF
|
260.2 KB
|
|
|
12 - Project Manager.mp4
|
MP4
|
8.1 MB
|
|
|
13 - Project Team Project Stakeholders.mp4
|
MP4
|
24.3 MB
|
|
|
14 - 3-6-PM.pdf
|
PDF
|
387 KB
|
|
|
14 - Project Management Tools.mp4
|
MP4
|
36.8 MB
|
|
|
15 - 4-1-PM.xlsx
|
XLSX
|
9 KB
|
|
|
15 - Project Diary for Generic Drug Development.mp4
|
MP4
|
12.4 MB
|
|
|
16 - 4-2-PM.xlsx
|
XLSX
|
24.9 KB
|
|
|
16 - Project Milestones for Generic Drug Development.mp4
|
MP4
|
15.4 MB
|
|
|
17 - 4-3-PM.xlsx
|
XLSX
|
41 KB
|
|
|
17 - Project Gantt Chart for Generic Drug Development.mp4
|
MP4
|
64.7 MB
|
|
|
18 - 4-4-PM.xlsx
|
XLSX
|
11.9 KB
|
|
|
18 - Generic Drug Development Project Phases.mp4
|
MP4
|
8.9 MB
|
|
|
19 - 5-1-PM-DeskResearch.pdf
|
PDF
|
345.5 KB
|
|
|
19 - Desk Research for Generic Drug Development.mp4
|
MP4
|
20.7 MB
|
|
|
2 - 2-1-PM.pdf
|
PDF
|
286.6 KB
|
|
|
2 - Active Pharmaceutical Ingredient API Finished Pharmaceutical Product FPP.mp4
|
MP4
|
25.7 MB
|
|
|
20 - 5-2-PM-DeskResearch.pdf
|
PDF
|
230.3 KB
|
|
|
20 - European Medicines Agency EMA.mp4
|
MP4
|
301.6 MB
|
|
|
21 - 5-3-1.pdf
|
PDF
|
2.9 MB
|
|
|
21 - 5-3-2.pdf
|
PDF
|
6.8 MB
|
|
|
21 - 5-3-PM-DeskResearch.pdf
|
PDF
|
167.6 KB
|
|
|
21 - World Health Organization WHO Food and Drug Administration FDA.mp4
|
MP4
|
284.9 MB
|
|
|
22 - 5-4-PM-DeskResearch.pdf
|
PDF
|
234.1 KB
|
|
|
22 - Pharmacopoeias Dailymed.mp4
|
MP4
|
115.7 MB
|
|
|
23 - 5-5-PM-DeskResearch.pdf
|
PDF
|
181.8 KB
|
|
|
23 - Drugscom.mp4
|
MP4
|
30.2 MB
|
|
|
24 - 5-6-PM-DeskResearch.pdf
|
PDF
|
238.4 KB
|
|
|
24 - DrugBank.mp4
|
MP4
|
121.1 MB
|
|
|
25 - 5-7-1.pdf
|
PDF
|
3.1 MB
|
|
|
25 - 5-7-PM-DeskResearch.pdf
|
PDF
|
190.5 KB
|
|
|
25 - Google Patents.mp4
|
MP4
|
194.6 MB
|
|
|
26 - 5-8-PM-DeskResearch.pdf
|
PDF
|
179.7 KB
|
|
|
26 - Espacenet.mp4
|
MP4
|
90.7 MB
|
|
|
27 - 6-1-PM-RawMaterialSelection.pdf
|
PDF
|
309.5 KB
|
|
|
27 - Raw Material Selection for Generic Drug Development.mp4
|
MP4
|
20.3 MB
|
|
|
28 - 6-2-PM-RawMaterialSelection.pdf
|
PDF
|
131.4 KB
|
|
|
28 - Evaluation of Characteristics of API.mp4
|
MP4
|
29.6 MB
|
|
|
29 - 6-3-PM-RawMaterialSelection.pdf
|
PDF
|
110.4 KB
|
|
|
29 - Stability Characteristics of API.mp4
|
MP4
|
19.5 MB
|
|
|
3 - 2-2-PM.pdf
|
PDF
|
282.4 KB
|
|
|
3 - Reference Listed Drug RLD Generic Multisource Pharmaceutical Products.mp4
|
MP4
|
69 MB
|
|
|
30 - 6-4-PM-RawMaterialSelection.pdf
|
PDF
|
124.3 KB
|
|
|
30 - Evaluation of Suppliers of API.mp4
|
MP4
|
21.2 MB
|
|
|
31 - 6-5-PM-RawMaterialSelection.pdf
|
PDF
|
130.2 KB
|
|
|
31 - Evaluation of Inactive Ingredient and Packaging Material.mp4
|
MP4
|
18.3 MB
|
|
|
32 - 7-1-PM-PreFormulationStudies.pdf
|
PDF
|
287.4 KB
|
|
|
32 - PreFormulation Studies for Generic Drug Development.mp4
|
MP4
|
8.1 MB
|
|
|
33 - 7-2-PM-PreFormulationStudies.pdf
|
PDF
|
122.8 KB
|
|
|
33 - Characterization of RLD.mp4
|
MP4
|
4.3 MB
|
|
|
34 - 7-3-PM-PreFormulationStudies.pdf
|
PDF
|
132.7 KB
|
|
|
34 - Defining Quality Target Product Profile QTPP.mp4
|
MP4
|
8 MB
|
|
|
35 - 74.mp4
|
MP4
|
3.8 MB
|
|
|
35 - Evaluation of BE Requirements.mp4
|
MP4
|
8.9 MB
|
|
|
36 - 7-5-PM-PreFormulationStudies.pdf
|
PDF
|
106.4 KB
|
|
|
36 - Evaluation of Inactive Ingredient Required for Formula.mp4
|
MP4
|
7.6 MB
|
|
|
37 - 7-6-PM-PreFormulationStudies.pdf
|
PDF
|
102.2 KB
|
|
|
37 - Compatibility Study.mp4
|
MP4
|
22.1 MB
|
|
|
38 - 7-7-PM-PreFormulationStudies.pdf
|
PDF
|
214 KB
|
|
|
38 - Supplying New material Apparatus Equipment.mp4
|
MP4
|
17.2 MB
|
|
|
39 - 7-8-PM-PreFormulationStudies.pdf
|
PDF
|
121 KB
|
|
|
39 - Performing PreFormulation Trials.mp4
|
MP4
|
12 MB
|
|
|
4 - 2-3-PM.pdf
|
PDF
|
246.2 KB
|
|
|
4 - Pharmaceutical Bioequivalency Therapeutic Equivalency.mp4
|
MP4
|
23.5 MB
|
|
|
40 - 8-1-PM-AMD-Studies.pdf
|
PDF
|
412.4 KB
|
|
|
40 - Analytical Method Development Studies for Generic Drug Development 1.mp4
|
MP4
|
12.8 MB
|
|
|
41 - 8-2-PM-AMD-Studies.pdf
|
PDF
|
214.6 KB
|
|
|
41 - Analytical Method Development Studies for Generic Drug Development 2.mp4
|
MP4
|
4.6 MB
|
|
|
42 - 8-3-PM-AMD-Studies.pdf
|
PDF
|
313.4 KB
|
|
|
42 - Literature Search for Analytical Method Development.mp4
|
MP4
|
14.3 MB
|
|
|
43 - 8-4-PM-AMD-Studies.pdf
|
PDF
|
270.9 KB
|
|
|
43 - Supplying Chemicals Materials Equipments.mp4
|
MP4
|
10.3 MB
|
|
|
44 - 8-5-PM-AMD-Studies.pdf
|
PDF
|
260.7 KB
|
|
|
44 - Performing Method Development Studies.mp4
|
MP4
|
11.8 MB
|
|
|
45 - 8-6-PM-AMD-Studies.pdf
|
PDF
|
281.1 KB
|
|
|
45 - Determining Acceptance Criteria.mp4
|
MP4
|
18.9 MB
|
|
|
46 - 8-7-PM-AMD-Studies.pdf
|
PDF
|
241.2 KB
|
|
|
46 - Determining Dissolution Parameters.mp4
|
MP4
|
10.5 MB
|
|
|
47 - 8-8-PM-AMD-Studies.pdf
|
PDF
|
219.5 KB
|
|
|
47 - Performing Stress Studies.mp4
|
MP4
|
14.4 MB
|
|
|
48 - 8-9-PM-AMD-Studies.pdf
|
PDF
|
238.6 KB
|
|
|
48 - Performing PreValidation Studies.mp4
|
MP4
|
20.5 MB
|
|
|
49 - 9-1-PM-FormulationforGDD.pdf
|
PDF
|
331.3 KB
|
|
|
49 - Formulation Studies for Generic Drug Development.mp4
|
MP4
|
11.4 MB
|
|
|
5 - 2-4-PM.pdf
|
PDF
|
261.9 KB
|
|
|
5 - Reference Listed Drug RLD Development.mp4
|
MP4
|
103.9 MB
|
|
|
50 - 9-2-PM-FormulationforGDD.pdf
|
PDF
|
225.4 KB
|
|
|
50 - Performing Formulation Trials.mp4
|
MP4
|
15.8 MB
|
|
|
51 - 9-3-PM-FormulationforGDD.pdf
|
PDF
|
261.7 KB
|
|
|
51 - Optimizing Formulation by using QBD.mp4
|
MP4
|
26.7 MB
|
|
|
52 - 9-4-PM-FormulationforGDD.pdf
|
PDF
|
177.3 KB
|
|
|
52 - Supplying Chemicals RawMaterials Equipments for Pilot Manufacturing.mp4
|
MP4
|
9.7 MB
|
|
|
53 - 9-5-PM-FormulationforGDD.pdf
|
PDF
|
312.2 KB
|
|
|
53 - Preparing Formulations for Critical Material Attributes CMA.mp4
|
MP4
|
34.9 MB
|
|
|
54 - 9-6-PM-FormulationforGDD.pdf
|
PDF
|
218.7 KB
|
|
|
54 - Preparing Formulations for Critical Quality Attribute CQA.mp4
|
MP4
|
11.6 MB
|
|
|
55 - 9-7-PM-FormulationforGDD.pdf
|
PDF
|
183.3 KB
|
|
|
55 - Preparing Formulations for Critical Process Parameter CPP.mp4
|
MP4
|
10.6 MB
|
|
|
56 - 9-8-PM-FormulationforGDD.pdf
|
PDF
|
238.6 KB
|
|
|
56 - Discriminitive Dissolution Parameters.mp4
|
MP4
|
35.3 MB
|
|
|
57 - 9-9-PM-FormulationforGDD.pdf
|
PDF
|
151.1 KB
|
|
|
57 - Compatibility Study with Final Formula Components.mp4
|
MP4
|
19.4 MB
|
|
|
58 - 10-1-PM-AnalyticalStudies.pdf
|
PDF
|
335.8 KB
|
|
|
58 - Analytical Studies for Generic Drug Development.mp4
|
MP4
|
37.3 MB
|
|
|
59 - Pilot Manufacturing for Generic Drug Development.mp4
|
MP4
|
30.3 MB
|
|
|
6 - 2-5-PM.pdf
|
PDF
|
181.3 KB
|
|
|
6 - Generic Drug Development.mp4
|
MP4
|
11.9 MB
|
|
|
60 - 12-1-PM-AnalysisofPilotBatches.pdf
|
PDF
|
341.4 KB
|
|
|
60 - Analysis of Pilot Batches for Generic Drug Development.mp4
|
MP4
|
35.4 MB
|
|
|
61 - 13-1-PM-BioequivalencyStudy.pdf
|
PDF
|
422 KB
|
|
|
61 - Performing Bioequivalency Study for Generic Drug Development.mp4
|
MP4
|
36.6 MB
|
|
|
62 - 14-1-PM-RegistrationDossier.pdf
|
PDF
|
454 KB
|
|
|
62 - Preparation Registration Dossier for Generic Drug Development.mp4
|
MP4
|
31.1 MB
|
|
|
63 - CONCLUSION-AYDANOZDEN.pdf
|
PDF
|
527.1 KB
|
|
|
63 - Conclusion.mp4
|
MP4
|
42.6 MB
|
|
|
7 - 2-6-PM.pdf
|
PDF
|
317.9 KB
|
|
|
7 - Comparision of Reference Listed Drug RLD Development Generic Drug Developmen.mp4
|
MP4
|
59.6 MB
|
|
|
8 - 2-7-PM.pdf
|
PDF
|
355.2 KB
|
|
|
8 - Invitro Invivo Studies for Drug Product.mp4
|
MP4
|
19.3 MB
|
|
|
9 - 3-1-PM.pdf
|
PDF
|
275.2 KB
|
|
|
9 - Project Elements of Project Cost Time Scope.mp4
|
MP4
|
22.6 MB
|
|
|
Bonus Resources.txt
|
TXT
|
409.6 B
|
|
|
Get Bonus Downloads Here.url
|
URL
|
204.8 B
|
